Chiome Bioscience Inc
TSE:4583
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
106
258
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
C
|
Chiome Bioscience Inc
TSE:4583
|
7.7B JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
238.1B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
167.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
83.6T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.8B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
40.5B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
277.8B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
29.1B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
20.3B EUR |
Loading...
|
Market Distribution
| Min | -125 500% |
| 30th Percentile | 4.2% |
| Median | 7% |
| 70th Percentile | 10.6% |
| Max | 9 743.7% |
Other Profitability Ratios
Chiome Bioscience Inc
Glance View
Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 37 full-time employees. The company went IPO on 2011-12-20. The firm operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Chiome Bioscience Inc is -125.7%, which is above its 3-year median of -162.9%.
Over the last 3 years, Chiome Bioscience Inc’s Operating Margin has increased from -251.7% to -125.7%. During this period, it reached a low of -251.7% on Aug 30, 2022 and a high of -123.2% on Mar 31, 2025.